Scientists piggyback experimental HIV vaccine on cold viruses

February 2, 2016 by Randy Dotinga, Healthday Reporter

(HealthDay)—Scientists report progress in their bid to develop ways to piggyback an HIV vaccine on germs that cause colds.

In the new study, Harvard researchers said they successfully used cold viruses to deliver an experimental HIV to humans.

The approach "appears to be safe and well-tolerated, and the injection induces a moderate immune response against HIV in humans," said Dr. James Crowe, director of Vanderbilt Vaccine Center in Nashville. He was not involved in the study.

The research doesn't mean that a long-sought HIV vaccine is near; these scientists focused on developing better ways to deliver a potential vaccine into the immune system.

Researchers have long sought to develop a vaccine against HIV, but the virus is especially stubborn.

"Most experimental vaccines tested to date don't seem to induce strong or protective immune responses," Crowe said. Even when they work well, he said, they tend to only prevent infection with a single strain and not the many strains of HIV that infect people.

In the study, the researchers piggybacked an experimental HIV vaccine onto two types of cold virus—adenovirus serotype 26 and adenovirus serotype 35. These cold viruses are rare, Crowe said, so most humans wouldn't have developed immunity to them.

The researchers then injected 217 healthy people not infected with HIV in Boston and parts of Africa (Kenya, Rwanda and South Africa) with at least one cold virus/HIV vaccine combo or a placebo. Seventy-eight percent of the subjects were black. Seven participants dropped out and didn't finish follow-up tests.

The findings showed that the cold viruses are a safe way to deliver the vaccine, and the vaccine triggered an immune response in most of the people, said study co-author Dr. Dan Barouch. He is director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and a professor of medicine at Harvard Medical School, both in Boston.

According to the study, nearly 16 percent of those who got the actual vaccine suffered moderate to severe problems near where they were injected. But the study authors said no one suffered severe side effects from the vaccine itself.

It's not clear if the effects of the vaccine will last past a year. The cost of vaccines using this approach is unknown, although Crowe said it's "cost-effective" to deliver vaccines into the body via cold viruses.

One expert noted another positive finding that came from the study.

"They also found out that giving two vaccines over three months is just as good as waiting until six months for the second dose," said Dr. Susan Buchbinder, director of the Bridge HIV research unit with the San Francisco Department of Public Health. "That is a big advantage, as more people are likely to complete their vaccination if the doses are closer together, and the , if protective, will start protecting them sooner."

The research was funded by several organizations, including the International AIDS Vaccine Initiative, the U.S. National Institutes of Health, and Crucell, a vaccine maker that's part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

What's next?

More research is needed to determine whether this strategy will protect people at risk of getting infected by HIV, Crowe said. Studies of this type are "quite large and complex," he said, and they're likely to require several years before the results are known.

Study co-author Barouch said this research is part of a larger effort to explore ways to piggyback vaccines onto cold viruses. Crucell has said that it's studying the use of these particular cold viruses to deliver an Ebola vaccine into the human body.

The study was published Feb. 2 in Annals of Internal Medicine.

Explore further: Breakthrough in the treatment of HIV—researchers develop prototype vaccine vector

More information: Full text of the study paper

For more about HIV vaccine research, visit the U.S. National Institute of Allergy and Infectious Diseases.

Related Stories

Breakthrough in the treatment of HIV—researchers develop prototype vaccine vector

November 16, 2015
A team of scientists at Royal Holloway, led by Professor George Dickson, and as part of the UK HIV Vaccine Consortium, led by Professor Jonathon Weber at Imperial College London, has developed a prototype HIV vaccine vector ...

HIV vaccine research must consider various immune responses

April 3, 2014
Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility ...

Investigational HIV vaccine regimen shows encouraging results in non-human primates

July 2, 2015
Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and several other collaborators today ...

Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination

October 1, 2014
Almost 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new cases per year. Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine development ...

UR tests HIV vaccine pill

January 14, 2015
Researchers at the University of Rochester Medical Center are testing a new oral vaccine to prevent infection with HIV, the virus that causes AIDS. The vaccine is unique because it is given as a pill, unlike most HIV vaccines ...

New technique paves the way for finding a HIV vaccine

November 5, 2015
Researchers are one step closer to finding an effective vaccine against HIV thanks to a new approach to systematically understanding the immune response to the virus.

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.